Research ArticleOriginal Article
Open Access

A novel biguanide-derivative promotes NEDD4-mediated FGFR1 ubiquitination through BMI1 to overcome osimertinib resistance in NSCLC

Mei Peng, Weifan Wang, Di Xiao, Duo Li, Jun Deng, Hui Zou, Xing Feng, Yunhai Yang, Songqing Fan and Xiaoping Yang
Cancer Biology & Medicine November 2025, 22 (11) 1381-1404; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0209

References

  1. 1.↵
    2. Herbst RS,
    3. Morgensztern D,
    4. Boshoff C.
    The biology and management of non-small cell lung cancer. Nature. 2018; 553: 446–54.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Siegel RL,
    3. Miller KD,
    4. Wagle NS,
    5. Jemal A.
    Cancer statistics, 2023. CA Cancer J Clin. 2023; 73: 17–48.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Lynch TJ,
    3. Bell DW,
    4. Sordella R,
    5. Gurubhagavatula S,
    6. Okimoto RA,
    7. Brannigan BW, et al.
    Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129–39.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    2. Paz-Ares L,
    3. Tan EH,
    4. O’Byrne K,
    5. Zhang L,
    6. Hirsh V,
    7. Boyer M, et al.
    Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017; 28: 270–7.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. Ramalingam SS,
    3. Yang JC,
    4. Lee CK,
    5. Kurata T,
    6. Kim DW,
    7. John T, et al.
    Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018; 36: 841–9.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Piper-Vallillo AJ,
    3. Sequist LV,
    4. Piotrowska Z.
    Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review. J Clin Oncol. 2020: JCO1903123.
  7. 7.
    2. Blaquier JB,
    3. Ortiz-Cuaran S,
    4. Ricciuti B,
    5. Mezquita L,
    6. Cardona AF,
    7. Recondo G.
    Tackling osimertinib resistance in EGFR-mutant non-small cell lung cancer. Clin Cancer Res. 2023; 29: 3579–91.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Taniguchi H,
    3. Yamada T,
    4. Wang R,
    5. Tanimura K,
    6. Adachi Y,
    7. Nishiyama A, et al.
    AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nat Commun. 2019; 10: 259.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Leonetti A,
    3. Sharma S,
    4. Minari R,
    5. Perego P,
    6. Giovannetti E,
    7. Tiseo M.
    Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019; 121: 725–37.
    OpenUrlCrossRefPubMed
  10. 10.↵
    2. Yang Z,
    3. Yang N,
    4. Ou Q,
    5. Xiang Y,
    6. Jiang T,
    7. Wu X, et al.
    Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018; 24: 3097–107.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    2. Park HR,
    3. Kim TM,
    4. Lee Y,
    5. Kim S,
    6. Park S,
    7. Ju YS, et al.
    Acquired resistance to third-generation EGFR tyrosine kinase inhibitors in patients with de novo EGFRT790M-mutant NSCLC. J Thorac Oncol. 2021; 16: 1859–71.
    OpenUrlPubMed
  12. 12.↵
    2. Turner N,
    3. Grose R.
    Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10: 116–29.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    2. Zhou Z,
    3. Liu Z,
    4. Ou Q,
    5. Wu X,
    6. Wang X,
    7. Shao Y, et al.
    Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases. Cancer Biol Med. 2021; 18: 490–501.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    2. Terp MG,
    3. Jacobsen K,
    4. Molina MA,
    5. Karachaliou N,
    6. Beck HC,
    7. Bertran-Alamillo J, et al.
    Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells. NPJ Precis Oncol. 2021; 5: 65.
    OpenUrlPubMed
  15. 15.↵
    2. Zhang P,
    3. Yue L,
    4. Leng Q,
    5. Chang C,
    6. Gan C,
    7. Ye T, et al.
    Targeting FGFR for cancer therapy. J Hematol Oncol. 2024; 17: 39.
    OpenUrlPubMed
  16. 16.↵
    2. Peng M,
    3. Deng J,
    4. Li X.
    Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer. Mol Cancer. 2024; 23: 256.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Babina IS,
    3. Turner NC.
    Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017; 17: 318–32.
    OpenUrlCrossRefPubMed
  18. 18.↵
    2. Zhao H,
    3. Swanson KD,
    4. Zheng B.
    Therapeutic repurposing of biguanides in cancer. Trends Cancer. 2021; 7: 714–30.
    OpenUrlPubMed
  19. 19.
    2. Hung MS,
    3. Chuang MC,
    4. Chen YC,
    5. Lee CP,
    6. Yang TM,
    7. Chen PC, et al.
    Metformin prolongs survival in type 2 diabetes lung cancer patients with EGFR-TKIs. Integr Cancer Ther. 2019; 18: 1534735419869491.
  20. 20.
    2. Arrieta O,
    3. Barrón F,
    4. Padilla MS,
    5. Avilés-Salas A,
    6. Ramírez-Tirado LA,
    7. Arguelles Jiménez MJ, et al.
    Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019; 5: e192553.
  21. 21.↵
    2. Li L,
    3. Jiang L,
    4. Wang Y,
    5. Zhao Y,
    6. Zhang XJ,
    7. Wu G, et al.
    Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced NSCLC patients with EGFR mutations: a randomized, double-blind phase II trial. Clin Cancer Res. 2019; 25: 6967–75.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    2. Guan A,
    3. Liu C,
    4. Yang X,
    5. Dekeyser M.
    Application of the intermediate derivatization approach in agrochemical discovery. Chem Rev. 2014; 114: 7079–107.
    OpenUrlPubMed
  23. 23.↵
    2. Bridges HR,
    3. Blaza JN,
    4. Yin Z,
    5. Chung I,
    6. Pollak MN,
    7. Hirst J.
    Structural basis of mammalian respiratory complex I inhibition by medicinal biguanides. Science. 2023; 379: 351–7.
    OpenUrlCrossRefPubMed
  24. 24.↵
    2. Xiao D,
    3. Lu Z,
    4. Wang Z,
    5. Zhou S,
    6. Cao M,
    7. Deng J, et al.
    Synthesis, biological evaluation and anti-proliferative mechanism of fluorine-containing proguanil derivatives. Bioorg Med Chem. 2020; 28: 115258.
  25. 25.↵
    2. Wang L,
    3. Fu H,
    4. Song L,
    5. Wu Z,
    6. Yu J,
    7. Guo Q, et al.
    Overcoming AZD9291 resistance and metastasis of NSCLC via ferroptosis and multitarget interference by nanocatalytic sensitizer plus AHP-DRI-12. Small. 2023; 19: e2204133.
  26. 26.↵
    2. Xu S,
    3. Cao Y,
    4. Luo Y,
    5. Xiao D,
    6. Wang W,
    7. Wang Z, et al.
    Synthesis, anti-proliferative evaluation and mechanism of 4-trifluoro methoxy proguanil derivatives with various carbon chain length. Molecules. 2021; 26: 5775.
    OpenUrlPubMed
  27. 27.↵
    2. Wang W,
    3. Xiao D,
    4. Zhou S,
    5. Xu S,
    6. Tang X,
    7. Zhou X, et al.
    Synthesis, anticancer activities, and mechanism of N-heptyl-containing biguanide derivatives. Med Chem. 2022; 18: 895–902.
    OpenUrlPubMed
  28. 28.↵
    2. Deng J,
    3. Peng M,
    4. Zhou S,
    5. Xiao D,
    6. Hu X,
    7. Xu S, et al.
    Metformin targets Clusterin to control lipogenesis and inhibit the growth of bladder cancer cells through SREBP-1c/FASN axis. Signal Transduct Target Ther. 2021; 6: 98.
    OpenUrlPubMed
  29. 29.↵
    2. Guo J,
    3. Deng N,
    4. Xu Y,
    5. Li L,
    6. Kuang D,
    7. Li M, et al.
    Bmi1 drives the formation and development of intrahepatic cholangiocarcinoma independent of Ink4A/Arf repression. Pharmacol Res. 2021; 164: 105365.
  30. 30.↵
    2. van Lohuizen M,
    3. Frasch M,
    4. Wientjens E,
    5. Berns A.
    Sequence similarity between the mammalian bmi-1 proto-oncogene and the Drosophila regulatory genes Psc and Su(z)2. Nature. 1991; 353: 353–5.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Kwon YT,
    3. Ciechanover A.
    The ubiquitin code in the ubiquitin-proteasome system and autophagy. Trends Biochem Sci. 2017; 42: 873–86.
    OpenUrlCrossRefPubMed
  32. 32.↵
    2. Wong A,
    3. Lamothe B,
    4. Lee A,
    5. Schlessinger J,
    6. Lax I.
    FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc Natl Acad Sci U S A. 2002; 99: 6684–9.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    2. Persaud A,
    3. Alberts P,
    4. Hayes M,
    5. Guettler S,
    6. Clarke I,
    7. Sicheri F, et al.
    Nedd4-1 binds and ubiquitylates activated FGFR1 to control its endocytosis and function. EMBO J. 2011; 30: 3259–73.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    2. Tang R,
    3. Langdon WY,
    4. Zhang J.
    Negative regulation of receptor tyrosine kinases by ubiquitination: key roles of the Cbl family of E3 ubiquitin ligases. Front Endocrinol (Lausanne). 2022; 13: 971162.
  35. 35.↵
    2. Fu K,
    3. Xie F,
    4. Wang F,
    5. Fu L.
    Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022; 15: 173.
    OpenUrlCrossRefPubMed
  36. 36.↵
    2. Tang ZH,
    3. Lu JJ.
    Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Lett. 2018; 420: 242–6.
    OpenUrlCrossRefPubMed
  37. 37.↵
    2. Rizo A,
    3. Olthof S,
    4. Han L,
    5. Vellenga E,
    6. de Haan G,
    7. Schuringa JJ.
    Repression of BMI1 in normal and leukemic human CD34(+) cells impairs self-renewal and induces apoptosis. Blood. 2009; 114: 1498–505.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    2. Zheng X,
    3. Wang Y,
    4. Liu B,
    5. Liu C,
    6. Liu D,
    7. Zhu J, et al.
    Bmi-1-shRNA inhibits the proliferation of lung adenocarcinoma cells by blocking the G1/S phase through decreasing cyclin D1 and increasing p21/p27 levels. Nucleic Acid Ther. 2014; 24: 210–6.
    OpenUrlPubMed
  39. 39.↵
    2. Crunkhorn S.
    Cancer: BMI1 inhibition reverses lung cancer. Nat Rev Drug Discov. 2016; 15: 678.
    OpenUrl
  40. 40.↵
    2. Yang D,
    3. Liu HQ,
    4. Yang Z,
    5. Fan D,
    6. Tang QZ.
    BMI1 in the heart: novel functions beyond tumorigenesis. EBioMedicine. 2021; 63: 103193.
  41. 41.
    2. Jia L,
    3. Zhang W,
    4. Wang CY.
    BMI1 inhibition eliminates residual cancer stem cells after PD1 blockade and activates antitumor immunity to prevent metastasis and relapse. Cell Stem Cell. 2020; 27: 238–53.e6.
    OpenUrlPubMed
  42. 42.↵
    2. Qin K,
    3. Lan X,
    4. Huang P,
    5. Saari MS,
    6. Khandros E,
    7. Keller CA, et al.
    Molecular basis of polycomb group protein-mediated fetal hemoglobin repression. Blood. 2023; 141: 2756–70.
    OpenUrlCrossRefPubMed
  43. 43.↵
    2. Zhang D,
    3. Han LL,
    4. Du F,
    5. Liu XM,
    6. Li J,
    7. Wang HH, et al.
    FGFR1 induces acquired resistance against gefitinib by activating AKT/mTOR pathway in NSCLC. Onco Targets Ther. 2019; 12: 9809–16.
    OpenUrlPubMed
  44. 44.↵
    2. Liu S,
    3. Hua Y,
    4. Wang J,
    5. Li L,
    6. Yuan J,
    7. Zhang B, et al.
    RNA polymerase III is required for the repair of DNA double-strand breaks by homologous recombination. Cell. 2021; 184: 1314–29.e10.
    OpenUrlCrossRefPubMed
  45. 45.↵
    2. Groelly FJ,
    3. Fawkes M,
    4. Dagg RA,
    5. Blackford AN,
    6. Tarsounas M.
    Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023; 23: 78–94.
    OpenUrlCrossRefPubMed
  46. 46.↵
    2. Huang RX,
    3. Zhou PK.
    DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020; 5: 60.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Subjects

Keywords